DexCom, Inc. (NASDAQ:DXCM) Stock Holdings Boosted by Intech Investment Management LLC

Intech Investment Management LLC raised its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 2,083.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 387,330 shares of the medical device company’s stock after purchasing an additional 369,587 shares during the quarter. Intech Investment Management LLC’s holdings in DexCom were worth $25,967,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jennison Associates LLC boosted its stake in DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after purchasing an additional 6,544,102 shares in the last quarter. Legal & General Group Plc boosted its stake in DexCom by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after purchasing an additional 49,076 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in DexCom by 16.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after purchasing an additional 353,019 shares in the last quarter. 1832 Asset Management L.P. boosted its stake in DexCom by 1.1% during the 1st quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company’s stock valued at $252,906,000 after purchasing an additional 20,400 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. boosted its stake in DexCom by 14.4% during the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 1,617,001 shares of the medical device company’s stock valued at $183,336,000 after purchasing an additional 203,043 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is owned by corporate insiders.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $75.24 on Thursday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The business has a fifty day simple moving average of $70.29 and a 200 day simple moving average of $90.44. The firm has a market cap of $29.39 billion, a price-to-earnings ratio of 45.05, a P/E/G ratio of 2.30 and a beta of 1.17.

Analysts Set New Price Targets

A number of equities analysts have issued reports on DXCM shares. UBS Group decreased their price target on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 26th. BTIG Research reduced their price objective on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Baird R W lowered DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Sanford C. Bernstein raised their price objective on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Finally, Royal Bank of Canada reduced their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.